Skip to main content

Neumora Therapeutics, Inc.

corporate_fare Company Profile

Neumora Therapeutics, Inc.

NMRA·NASDAQ·Life Sciences·CIK 0001885522

Neumora is a clinical-stage biopharmaceutical company focused on developing novel therapies with brain-penetrant chemistry. The company's therapeutic pipeline targets a range of underserved, prevalent diseases, including neurodegenerative diseases, neuropsychiatric diseases, and metabolic disorders. Neumora is advancing a Phase 3 program for navacaprant, a once-daily oral kappa opioid receptor ("KOR") antagonist, for the treatment of major depressive disorder ("MDD"). Additionally, the company is developing NMRA-511, a highly selective antagonist of the vasopressin 1a receptor ("V1aR"), for the treatment of agitation associated with dementia due to Alzheimer's disease ("AD"). Neumora's pipeline also includes NMRA-898, a novel M4 PAM for the treatment of schizophrenia, and NMRA-215, a highly brain-penetrant, oral NLRP3 inhibitor for the treatment of obesity. The company expects to report Phase 3 KOASTAL-2 and -3 topline data in the second quarter of 2026, MAD extension data with NMRA-511 in the second half of 2026, and multiple ascending dose ("MAD") data with NMRA-898 in the second half of 2026. Neumora has scaled its pipeline through internal discovery and business development activities.

Neumora Therapeutics, Inc. (NASDAQ:NMRA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for NMRA at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Neumora Reports Positive Phase 1b Results for NMRA-511 in Alzheimer's Agitation; Advances Pipeline

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$236.93M
Diluted EPS
-$1.45
Op. Cash Flow
-$206.44M
Operating Income
-$241.16M
Cash & Equivalents
$182.53M
Total Debt
$54.53M
Debt / Equity
0.52×
Shares Outstanding
174.26M sh
Source: 10-K · filed 2026-03-30 · accession 0001193125-26-130388
$0.32 -4.16% today
52-week range · as of 2026-11-16 $0.3154 – $3.65
Market cap
$63.01M
Volume
1.1M (0.6× avg)
3-mo avg 1.8M
Live data · 2026-11-21 16:05 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed NMRA - Filings & News (Page 2)

NMRA
Jan 05, 2026, 6:45 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.86
Real-time Price: $0.320 info
Change: -$1.54 (-83%) info
Market Cap: $63.005M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets